The “Anti-CD19 Antibody – Pipeline Insights, 2018″ report covers an in-depth analysis of Anti-CD19 Antibody drug molecules currently undergoing clinical studies.
It provides a deep understanding of potential Anti-CD19 Antibody drug molecules across all drug development phases. The report assesses the pipeline Anti-CD19 Antibody molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products), molecule type (Small molecules, Biologics and others), drug target, mechanism of action (MoA), and route of administration (oral, IV, and others). The report provides a snapshot of discontinued and dormant drugs too.
In addition, the report includes key insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
The report covers company profiles key players in developing Anti-CD19 Antibody drug molecules. The company profile includes key info on overview, financial highlights, product portfolio, business strategies, and key recent developments.
Get your free sample proposal with a single click!